B. Riley assumed coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research report sent to investors on Friday, January 5th, MarketBeat reports. The brokerage issued a neutral rating and a $3.00 target price on the biotechnology company’s stock.
Several other research analysts have also weighed in on the company. BidaskClub raised Arrowhead Pharmaceuticals from a hold rating to a buy rating in a research report on Wednesday, December 27th. Cantor Fitzgerald set a $2.00 target price on Arrowhead Pharmaceuticals and gave the stock a hold rating in a research report on Tuesday, December 12th. Chardan Capital reaffirmed a neutral rating on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, September 13th. William Blair upgraded Arrowhead Pharmaceuticals from a market perform rating to an outperform rating in a report on Monday, September 18th. Finally, Piper Jaffray Companies upgraded Arrowhead Pharmaceuticals from a neutral rating to an overweight rating and set a $5.50 price target for the company in a report on Monday, November 27th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the stock. Arrowhead Pharmaceuticals has an average rating of Hold and an average target price of $3.13.
Arrowhead Pharmaceuticals (ARWR) opened at $5.04 on Friday. Arrowhead Pharmaceuticals has a 52 week low of $1.42 and a 52 week high of $5.47. The firm has a market capitalization of $377.13, a price-to-earnings ratio of -10.72 and a beta of 1.79. The company has a current ratio of 3.63, a quick ratio of 3.63 and a debt-to-equity ratio of 0.03.
In other news, COO Bruce D. Given sold 20,000 shares of the stock in a transaction dated Monday, January 1st. The shares were sold at an average price of $3.69, for a total transaction of $73,800.00. Following the transaction, the chief operating officer now owns 948,356 shares of the company’s stock, valued at $3,499,433.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 4.57% of the company’s stock.
Hedge funds have recently modified their holdings of the company. Virtu KCG Holdings LLC lifted its position in shares of Arrowhead Pharmaceuticals by 115.6% during the second quarter. Virtu KCG Holdings LLC now owns 99,267 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 53,215 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in Arrowhead Pharmaceuticals by 252.2% in the third quarter. Dimensional Fund Advisors LP now owns 44,358 shares of the biotechnology company’s stock worth $192,000 after acquiring an additional 31,765 shares during the last quarter. Schwab Charles Investment Management Inc. lifted its holdings in Arrowhead Pharmaceuticals by 10.4% in the third quarter. Schwab Charles Investment Management Inc. now owns 171,249 shares of the biotechnology company’s stock worth $742,000 after acquiring an additional 16,103 shares during the last quarter. Allianz Asset Management GmbH bought a new position in Arrowhead Pharmaceuticals in the third quarter worth about $1,958,000. Finally, ING Groep NV bought a new position in Arrowhead Pharmaceuticals in the third quarter worth about $3,500,000. 20.05% of the stock is currently owned by institutional investors and hedge funds.
About Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.